(Q36439004)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

3

Howard Chertkow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

Serge Gauthier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Howard H Feldman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

David K Conn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Morris Freedman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Macknight Chris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2nd Canadian Conference on Antidementia Guidelines

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

6-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

Five-Year Outcomes for Dementia Defined Solely by Neuropsychological Test Performance

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Misclassification is likely in the assessment of mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The Recognition, Assessment and Management of Dementing Disorders: Conclusions from the Canadian Consensus Conference on Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Neurochemical features of frontotemporal dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Altered serotonergic and cholinergic synaptic markers in Pick's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Epidemiology of frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The prevalence of frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Differential validity of psychometric tests in dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Behavioral symptoms in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Pharmacotherapeutic approaches to the prevention of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The needs of the caregiver in the long-term treatment of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Severe impairment battery. A neuropsychological test for severely demented patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Comparison of dementia-specific quality of life measures in adult day centers

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Assessing quality of life in older adults with cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Quality of life measures for nursing home residents.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The classification, genetics and neuropathology of frontotemporal dementia. Introduction to the special topic papers: Part I.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A model for quality of life measures in patients with dementia: Lawton's next step.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Relationship between Alzheimer's disease severity and patient participation in decisions about their medical care.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Donepezil in vascular dementia: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Pathological verification of ischemic score in differentiation of dementias.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Ginkgo biloba and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Factor analysis of the frontal systems behavior scale (FrSBe).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Assessing frontal lobe behavioral syndromes with the frontal lobe personality scale

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Aging-Associated Cognitive Decline

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Impact of donepezil on caregiving burden for patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Utility-weighted measures of quality of life in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

EQ-5D in patients with dementia: an investigation of inter-rater agreement.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Goal setting and attainment in Alzheimer's disease patients treated with donepezil

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Unicorns do exist: a tutorial on "proving" the null hypothesis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Placebo or Active Control Trials of Antipsychotic Drugs?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Frontotemporal Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Classification criteria for mild cognitive impairment: a population-based validation study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Emerging therapies for vascular dementia and vascular cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Cornell Scale for Depression in Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

https://api.crossref.org/works/10.1017%2FS0317167100004649

1 reference

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Factors attenuating the validity of the Geriatric Depression Scale in a dementia population.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Spectrum of disease in vascular cognitive impairment.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Use of the Geriatric Depression Scale in dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Quality of Life measures for dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Subcortical ischaemic vascular dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Current pharmacologic options for patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Quality of Life in Dementia: state of the art--report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer's Society satellite meeting.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Frontotemporal dementia: a randomised, controlled trial with trazodone

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Outcome measures in Alzheimer's disease: do they go far enough?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Bedside assessment of executive cognitive impairment: the executive interview

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Orbitofrontal function, object alternation and perseveration.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The FAB: a Frontal Assessment Battery at bedside.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The Global Deterioration Scale for assessment of primary degenerative dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Reliability of NINCDS-ADRDA clinical criteria for the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A new clinical scale for the staging of dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Validation of clinical diagnostic criteria for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clinicopathological Validation Study of Four Sets of Clinical Criteria for Vascular Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Metal-protein attenuating compounds and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Insights from modeling the tertiary structure of human BACE2.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Current progress in beta-amyloid immunotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Current progress on new therapies for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004649

7 January 2021

10.1017/S0317167100004649

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16583717%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference